help button home button Endocrine Society Molecular Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on March 13, 2007
Molecular Endocrinology, doi:10.1210/me.2006-0468
A more recent version of this article appeared on May 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
21/5/1039    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moehren, U.
Right arrow Articles by Baniahmad, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moehren, U.
Right arrow Articles by Baniahmad, A.

Submitted on November 9, 2006
Accepted on March 6, 2007

Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth

Udo Moehren, Maria Papaioannou, Christina A. Reeb, Wei Hong, and Aria Baniahmad*

Institute of Human Genetics and Anthropology, Medical Faculty, Kollegiengasse 10, 07743 Jena, Germany

* To whom correspondence should be addressed. E-mail: aban{at}mti.uni-jena.de.

Prostate cancer cell growth is initially androgen-dependent. Androgen antagonists are used in prostate cancer therapy to inactivate the transcriptional activity of the human androgen receptor (hAR) and to inhibit the proliferation of prostate cancer. Here, we have characterized Alien with characteristics of a corepressor as a novel interacting factor for the antagonist bound hAR. Alien is recruited to hAR in the presence of the AR antagonist cyproterone acetate (CPA). The interaction of Alien with hAR is verified in vivo and in vitro by a modified mammalian 2-hybrid system, co-immunoprecipitation (Co-IP), chromatin-immunoprecipitation (ChIP), and in vitro binding assays. In contrast to other nuclear receptors Alien binds to the amino-terminus of hAR with the receptor SUMOylation sites being involved. Furthermore, cellular localization of Alien is changed towards a predominant nuclear localization upon treatment of prostate cancer cells with CPA. Notably, stable expression of Alien in LNCaP cells inhibits both endogenous PSA expression and proliferation of these cells in the presence of CPA but not in the presence of an AR agonist. These findings underline the importance of corepressors for inhibition of prostate cancer cell growth by androgen antagonists.


Key words: antihormone • androgen antagonist • LNCaP • co-repressor • prostate cancer

NURSA Molecule Pages Link:

Nuclear Receptors:   AR
Coregulators:   Alien  |  SMRT
Ligands:   Dihydrotestosterone  |  Mifepristone  |  Bicalutamide  |  R1881



This article has been cited by other articles:


Home page
FASEB J.Home page
U. Moehren, M. Papaioannou, C. A. Reeb, A. Grasselli, S. Nanni, M. Asim, D. Roell, I. Prade, A. Farsetti, and A. Baniahmad
Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development
FASEB J, April 1, 2008; 22(4): 1258 - 1267.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. V. Heemers and D. J. Tindall
Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex
Endocr. Rev., December 1, 2007; 28(7): 778 - 808.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society